Gliovac/ERC1671/SITOIGANAP
Recurrent Glioblastoma Multiforme (GBM)
Phase 2Active
Key Facts
Indication
Recurrent Glioblastoma Multiforme (GBM)
Phase
Phase 2
Status
Active
Company
About Epitopoietic Research
ERC is a Belgian clinical-stage biotech pioneering a unique, patented cell-based immunotherapy for solid tumors, with a primary focus on recurrent glioblastoma (GBM). Its lead vaccine, Gliovac/ERC1671, combines autologous and allogeneic tumor cells to stimulate a potent anti-cancer immune response and has shown promising survival extensions in compassionate use. While advancing its GBM program through clinical trials, the company is also leveraging its platform to develop vaccines for viral infections, though it faces challenges typical of early-stage biotechs, including clinical validation and funding.
View full company profileTherapeutic Areas
Other Recurrent Glioblastoma Multiforme (GBM) Drugs
| Drug | Company | Phase |
|---|---|---|
| OKN-007 | Oblato | Phase 2 |
| Alpha DaRT | Alpha Tau Medical | Pre-Clinical |